You are here

  • Home
  • Archive
  • Volume 81, Issue 3
  • Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Citation Tools

Article menu
Psoriatic arthritis
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Coates LC, Gossec L, Theander E, et al
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS)
Annals of the Rheumatic Diseases 2022;81:359-369.